Data for good
Improving and extending lives by learning from the experience of every person with cancer
Flatiron unlocks the power of deidentified patient data, so every person’s experience can inform and improve outcomes for future patients. We do this by capturing real-world experiences as data points. With our partnerships across research and care, these data points can bring the cancer care ecosystem into the future.
For a peek into how we keep clinicians up-to-date on the most innovative treatment options, watch our episode below from BBC StoryWorks ‘Nature’s Building Blocks’ series.

From curating high-quality real-world data to surfacing evidence-based treatment options at the point of care, Flatiron Health is using Data for Good.
Point of care
We use technology to transform data into knowledge and actionable insights, enabling clinicians to offer the best treatment options for their patients in real time.
Real-world evidence
We generate integrated RWE solutions that inform and accelerate research, leading to expanded treatment options for patients.
Clinical research
We are transforming clinical research through technology that seamlessly integrates research and increases trial access at the point of care.
International
We are accelerating cancer research and improving the quality of care globally, using real-world evidence to improve patient outcomes, inform policy and advance research.
How we're using Data for Good
These are just some of the recent examples of evidence accelerating research. These insights are then brought directly back to the point of care through Flatiron technology, closing the gap between care and research.
This is critically important for clinicians, for people with cancer, and for their families.
Dosing
Patients with EGFR-mutations for some cancers now have an alternative, more convenient, dosing regimen (and more time to live their lives).
Safety
Women with certain heart conditions and HER2+ metastatic breast cancer now have access to a new treatment option.